Yes

Vasodilator

Considered as "possibly effective" for adjunctive therapy in peripheral vascular disease and possibly senility due to cerebrovascular disease or multi-infarct dementia; migraine prophylaxis, vertigo, tinnitus, and visual disturbances secondary to cerebrovascular insufficiency and diabetic peripheral polyneuropathy

C

Hypersensitivity to cyclandelate or any component

<1%:

Central nervous system: Headache, pain, dizziness; tingling sensation in face, fingers, or toes

Gastrointestinal: Belching, heartburn

Neuromuscular & skeletal: Weakness

May enhance action of drugs causing vasodilation/hypotension

Cyclandelate, 3,3,5-trimethylcyclohexyl mandelate is a vasodilator that exerts a direct, papaverine-like action on smooth muscles, particularly that found within the blood vessels. Animal data indicate that cyclandelate also has antispasmodic properties; exhibits no adrenergic stimulation or blocking action; action exceeds that of papaverine; mild calcium channel blocking agent, may benefit in mild hypercalcemia; calcium channel blocking activity may explain some of its pharmacologic effects (enhanced blood flow) and inhibition of platelet aggregation.

Adults: Oral: Initial: 1.2-1.6 g/day in divided doses before meals and at bedtime until response; maintenance therapy: 400-800 mg/day in 2-4 divided doses; start with lowest dose in elderly due to hypotensive potential; decrease dose by 200 mg decrements to achieve minimal maintenance dose; improvement can usually be seen over weeks of therapy and prolonged use; short courses of therapy are usually ineffective and not recommended

May cause dizziness

None reported

No information available to require special precautions

No effects or complications reported

Take with meals or antacids to reduce GI distress

Capsule: 200 mg, 400 mg

Tablet: 200 mg, 400 mg